The Vasoactive Mas Receptor in Essential Hypertension

Area of Science:

• Cardiovascular Physiology
• Endocrinology
• Hypertension Research

Background:

• The renin-angiotensin-aldosterone system (RAAS) is crucial for vascular control but is more complex than initially understood.
• Two counteracting axes exist: the vasoconstrictive axis (AT1R) and the vasorelaxant axis (MasR).
• Essential hypertension, a global health issue, requires further elucidation of its pathophysiology.

Purpose of the Study:

• To explore the potential of the vasorelaxant Mas receptor axis as a therapeutic target for hypertension.
• To review the current understanding of the RAAS, focusing on the MasR pathway.
• To highlight the need for further research into MasR's clinical potential.

Main Methods:

• Review of existing literature on the RAAS and its components.
• Analysis of the counteracting roles of the AT1R and MasR axes in vascular control.
• Examination of studies involving angiotensin-(1-7), MasR agonists, and related molecules.

Main Results:

• The RAAS comprises a classical vasoconstrictive axis and an opposing vasorelaxant axis.
• The vasorelaxant axis, involving angiotensin-(1-7) and MasR, shows promise for hypertension therapy.
• Current pharmacological strategies primarily target the classical RAAS axis.

Conclusions:

• The MasR axis presents a novel therapeutic avenue for hypertension, distinct from classical RAAS inhibition.
• Further investigation is needed to clarify the clinical utility of MasR due to complex physiological interactions.
• Understanding the full potential of MasR requires exploring its biased activities and signaling pathways.